SCHEMBL5028895

SCHEMBL5028895

CC(C)(C)NC(=O)c1sc2nc(-c3ccccc3)nc(-c3cccc(NC(=O)CCl)c3)c2c1N

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LHCGR P22888 7/20 0.54
FSHR P23945 2/20 0.54
TSHR P16473 2/20 0.53
BRAF P15056 9/20 0.47
CHRM4 P08173 1/20 0.42
MITF O75030 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
JAK3 P52333 1/20 0.41
SRC P12931 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5028901 0.92 LHCGR (0.54) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL5030954 0.90 LHCGR (0.51) LHCGRFSHRTSHRBRAFALDH1A1
SCHEMBL6220667 0.87 LHCGR (0.53) LHCGRFSHRTSHRBRAFRAB9A
SCHEMBL4426367 0.87 LHCGR (0.55) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL5026187 0.86 LHCGR (0.52) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL6224284 0.85 LHCGR (0.50) LHCGRFSHRTSHRBRAFMAPT
SCHEMBL5026098 0.85 LHCGR (0.62) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL5037256 0.83 LHCGR (0.51) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL6222798 0.83 LHCGR (0.51) LHCGRFSHRTSHRBRAFCHRM4
SCHEMBL5036580 0.82 LHCGR (0.50) LHCGRFSHRTSHRBRAFRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375109-B2 Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity N.V. ORGANON (NL) 2008-05-20 US disclosed
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR LHCGR 3/4885FSHR 1/4885TSHR 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.